Conference call to be held on September 29 hosted by Piper Sandler.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Positive Buy Rating for BridgeBio Pharma’s Encaleret Driven by Promising Phase 2 Results and Significant Market Potential
- BridgeBio price target raised to $82 from $72 at UBS
- Optimistic Buy Rating for BridgeBio Pharma: Promising ADH1 Treatment and Market Potential
- BridgeBio Pharma: Poised for Growth with Promising Pipeline and Upcoming Catalysts
- BridgeBio Pharma’s Encaleret: Promising Developments and Potential Market Impact